Search Result

Results for "

peripheral system

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (8) Adrenergic Receptor (4) Apelin Receptor (APJ) (1) Apoptosis (1) Aryl Hydrocarbon Receptor (1) Autophagy (1) Calcium Channel (1) Cannabinoid Receptor (2) CGRP Receptor (2) CRFR (1) Dopamine Receptor (1) Drug Derivative (1) FAAH (1) GABA Receptor (2) GPR35 (1) HDAC (2) Integrin (1) mAChR (1) Molecular Glues (3) nAChR (3) NAMPT (1) Opioid Receptor (7) P2X Receptor (1) Prostaglandin Receptor (1) Sodium Channel (3) STAT (3) Thyroid Hormone Receptor (1) Trk Receptor (1)
By Research Areas:	Cancer (10) Cardiovascular Disease (7) Endocrinology (3) Inflammation/Immunology (7) Metabolic Disease (2) Neurological Disease (37)

By Targets:

5-HT Receptor (8)

Adrenergic Receptor (4)

Apelin Receptor (APJ) (1)

Apoptosis (1)

Aryl Hydrocarbon Receptor (1)

Autophagy (1)

Calcium Channel (1)

Cannabinoid Receptor (2)

CGRP Receptor (2)

CRFR (1)

Dopamine Receptor (1)

Drug Derivative (1)

FAAH (1)

GABA Receptor (2)

GPR35 (1)

HDAC (2)

Integrin (1)

mAChR (1)

Molecular Glues (3)

nAChR (3)

NAMPT (1)

Opioid Receptor (7)

P2X Receptor (1)

Prostaglandin Receptor (1)

Sodium Channel (3)

STAT (3)

Thyroid Hormone Receptor (1)

Trk Receptor (1)

By Research Areas:

Cancer (10)

Cardiovascular Disease (7)

Endocrinology (3)

Inflammation/Immunology (7)

Metabolic Disease (2)

Neurological Disease (37)

Inhibitors & Agonists

Screening Libraries

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Targets Recommended: Complement System

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-131728

GPR35 agonist 3	GPR35	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
GPR35 agonist 3 is a synthetic GPR35 agonist with an EC₅₀value of 1.4 μM. GPR35 agonist 3 can be used for the research of various diseases, such as gastric cancer, type 2 diabetes, cardiovascular diseases, immune system and peripheral nervous system .

HY-163855

KGP-25	Sodium Channel GABA Receptor	Neurological Disease
KGP-25 is an inhibitor of voltage-gated sodium channel 1.8 (Nav1.8), which can be used for analgesia by targeting Nav1.8 in the peripheral nervous system (PNS). KGP-25 can also target γ-aminobutyric acid subtype A receptor (GABA_A) in the central nervous system (CNS) for general anesthesia .

HY-B0954

Oxyphencyclimine hydrochloride	mAChR	Neurological Disease
A new tertiary amine, Oxyphencyclimine hydrochloride，has been investigated for its effects on the peripheral parasympathetic system.

HY-160092A

Martinostat hydrochloride	HDAC	Neurological Disease
Martinostat hydrochloride is a HDAC inhibitor and can be labeled with radionuclides for quantitative imaging of HDACs in vivo in the central nervous system and major peripheral organs .

HY-P2719

Fibronectin Type III Connecting Segment Fragment 1-25	Integrin	Neurological Disease
Fibronectin Type III Connecting Segment Fragment 1-25 is a peptide that is responsible for melanoma cell adhesion, and plays an important role in development of the peripheral nervous system in chicken .

HY-169844

D-19050	Drug Derivative	Neurological Disease
D-19050 is a derivative of triaminopyridine and is an analgesic with both central and peripheral effects .

HY-118209

L 646462	Dopamine Receptor 5-HT Receptor	Neurological Disease
L-646462 is an antagonist of dopamine and 5-HT, with selectivity for the peripheral system (the central/peripheral activity ratio of L-646462 is 143). L-646462 can be used in research related to nausea, vomiting, and associated neurological disorders .

HY-160092

Martinostat	HDAC	Neurological Disease
Martinostat is a HDAC inhibitor and can be labeled with radionuclides for quantitative imaging of HDACs in vivo in the central nervous system and major peripheral organs .

HY-134173

Arachidonoyl ethanolamide phosphate	Cannabinoid Receptor Apoptosis	Neurological Disease
Arachidonoyl ethanolamide phosphate, an endocannabinoid, is an endogenous ligand for cannabinoid receptors in the central nervous system (CB1 subtype) and peripheral immune cells (CB2 subtype) .

HY-106147

Frakefamide	Opioid Receptor	Neurological Disease
Frakefamide is a potent analgesic that acts as a peripheral active μ-selective receptor agonist. Frakefamide is unable to penetrate the blood-brain-barrier and enter the central nervous system .

HY-P1253

α-Endorphin (human)	Opioid Receptor	Neurological Disease
α-Endorphin (human) is a neuropeptide, that acts on the central nervous system (CNS) and peripheral nervous system (PNS). α-Endorphin (human) binds μ-opioid receptor, and exhibits analgesic efficacy. α-Endorphin (human) regulates sexual behaviors and pleasure felling .

HY-106147B

Frakefamide TFA	Opioid Receptor	Neurological Disease
Frakefamide TFA is a potent analgesic that acts as a peripheral active μ-selective receptor agonist. Frakefamide is unable to penetrate the blood-brain-barrier and enter the central nervous system .

HY-122281

JTE 7-31	Cannabinoid Receptor	Others
JTE 7-31 selectively acts on peripheral cannabinoid receptors, minimizing central nervous system side effects. They exhibit potent immunomodulatory, anti-inflammatory and anti-allergic properties, as well as inhibitory effects on nephritis .

HY-N0746

Oxysophocarpine 4 Publications Verification	Others	Cancer
Oxysophocarpine is an alkaloid extracted from Sophora alopecuroides.?Oxysophocarpine has neuroprotective and anti-nociceptive effects on the central and peripheral nervous systems . Oxysophocarpine inhibits the?growth?and?metastasis?of ?oral?squamous?cell?carcinoma?(OSCC) .

HY-14790

Esreboxetine (S,S)-Reboxetine	Adrenergic Receptor	Neurological Disease
Esreboxetine ((S,S)-Reboxetine) is a selective norepinephrine reuptake inhibitor with activity in increasing urethral resistance. Esreboxetine has been reported to be effective in patients with stress urinary incontinence in a Phase IIa clinical study, achieving this effect by increasing urethral closure. The mechanism of action of esreboxetine involves inhibition of norepinephrine transporters in the central and peripheral nervous systems. The peripheral selectivity of esreboxetine helps it significantly increase urethral resistance without penetrating the brain .

HY-16723

Funapide TV 45070; XEN402	Sodium Channel	Neurological Disease Inflammation/Immunology
Funapide (TV 45070; XEN402) is a potent inhibitor of the sodium channel Nav1.7, Nav1.8 and other Nav channels expressed in the peripheral nervous system. Fornabil is an orally effective analgesic agent .

HY-P1071A

α-CGRP(human) TFA 2 Publications Verification Calcitonin gene-related peptide TFA	CGRP Receptor	Cardiovascular Disease
α-CGRP(human) (TFA) is a regulatory neuropeptide of 37 amino acids. α-CGRP(human) (TFA) is widely distributed in the central and peripheral nervous system. α-CGRP(human) (TFA) is a potent vasodilator and has inotropic and chronotropic effects .

HY-16723A

(R)-Funapide (R)-TV 45070; (R)-XEN402	Sodium Channel	Neurological Disease Inflammation/Immunology
(R)-Funapide ((R)-TV 45070) is the less active R-enantiomer of Funapide. Funapide is a potent inhibitor of the sodium channel Nav1.7, Nav1.8 and other Nav channels expressed in the peripheral nervous system. Fornabil is an orally effective analgesic agent .

HY-B0206

Rizatriptan benzoate MK 462	5-HT Receptor	Neurological Disease
Rizatriptan benzoate is the agonist for 5-HT_1B and 5-HT_1D. Rizatriptan benzoate has a peripheral vasoconstrictive effect, penetrates the intact blood-brain barrier, and inhibits pain neurotransmission in the central nervous system .

HY-P1071

α-CGRP(human) 2 Publications Verification Calcitonin gene-related peptide	CGRP Receptor	Cardiovascular Disease
α-CGRP(human) (Calcitonin gene-related peptide) is a regulatory neuropeptide of 37 amino acids. α-CGRP(human) is widely distributed in the central and peripheral nervous system. α-CGRP(human) is a potent vasodilator and has inotropic and chronotropic effects .

HY-130670

CGP 54626A free base	GABA Receptor	Neurological Disease
CGP 54626A (free base) is a GABAB receptor modulator, which is essential in the central and peripheral nervous systems. It is used as a tool to identify and characterize GABAB receptor agonists and antagonists, which will aid in the development of drugs targeting diseases related to these systems. This discovery involves purified GABAB receptors, receptor proteins and their encoding nucleic acids, facilitating the study of new members of the GABAB receptor family through DNA cloning technology and sequence-derived probes .

HY-P10110

retro-inverso TAT-Beclin 1 (D-amino acid)	Autophagy	Neurological Disease
retro-inverso TAT-Beclin 1 D-amino acid is has higher activity and resistance to proteolytic degradation in vivo compared to L-amino acids peptide. TAT-Beclin 1 can induce autophagy in peripheral tissues in adult mice as well as in the central nervous system of neonatal mice .

HY-N0746R

Oxysophocarpine (Standard)	Others	Cancer
Oxysophocarpine (Standard) is the analytical standard of Oxysophocarpine. This product is intended for research and analytical applications. Oxysophocarpine is an alkaloid extracted from Sophora alopecuroides. Oxysophocarpine has neuroprotective and anti-nociceptive effects on the central and peripheral nervous systems . Oxysophocarpine inhibits the growth and metastasis of oral squamous cell carcinoma (OSCC) .

HY-B0311D

Carbidopa hydrochloride (S)-(-)-Carbidopa hydrochloride	Aryl Hydrocarbon Receptor	Cancer
Carbidopa hydrochloride ((S)-(-)-Carbidopa hydrochloride) is a drug used to inhibit Parkinson's disease, which has the activity of inhibiting the peripheral metabolism of levodopa. Carbidopa hydrochloride can increase the proportion of peripheral levodopa penetrating the blood-brain barrier, thereby enhancing its effect on the central nervous system. Carbidopa hydrochloride has also been found to be an aryl hydrocarbon receptor (AhR) ligand with anticancer activity, which can inhibit the growth of pancreatic cancer cells and tumors. The selective AhR regulation properties of carbidopa hydrochloride provide potential prospects for its clinical application .

HY-12560A

PNU-282987 Maximum Cited Publications 11 Publications Verification	nAChR 5-HT Receptor	Neurological Disease
PNU-282987 is a potent α7 nicotinic acetylcholine receptor (nAChR) agonist with an EC₅₀ of 154 nM. PNU-282987 is also a functional antagonist of the 5-HT₃ receptor with an IC₅₀ of 4541 nM. PNU-282987 can be used for the research of central and peripheral nervous systems .

HY-P99221

Tanezumab RN-624; PF 4383119	Trk Receptor	Neurological Disease Inflammation/Immunology Cancer
Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia .

HY-121670

Ambenoxan	Others	Neurological Disease
Ambenoxan is a central nervous system-acting skeletal muscle relaxant that is effective in mice, rats, rabbits, dogs, and monkeys without loss of the righting reflex. It has no peripheral neuromuscular blocking effects and significantly reduces or eliminates decerebrate rigidity in rabbits, but does not antagonize the effects of strychnine, leptazol, or tremorine. Like other central nervous system depressants, ambenoxan prolongs sleep duration with hexobarbitone, but it has no local anesthetic effects. In anesthetized cats, the agent lowers blood pressure and reduces the pressor response to epinephrine, but has no effect on norepinephrine.

HY-121670A

Ambenoxan hydrochloride	Adrenergic Receptor	Neurological Disease
Ambenoxan hydrochloride is a central nervous system-acting skeletal muscle relaxant that is effective in mice, rats, rabbits, dogs, and monkeys without loss of the righting reflex. It has no peripheral neuromuscular blocking effects and significantly reduces or eliminates decerebrate rigidity in rabbits, but does not antagonize the effects of strychnine, leptazol, or tremorine. Like other central nervous system depressants, ambenoxan prolongs sleep duration with hexobarbitone, but it has no local anesthetic effects. In anesthetized cats, the agent lowers blood pressure and reduces the pressor response to epinephrine, but has no effect on norepinephrine.

HY-108960

PPADS	P2X Receptor	Inflammation/Immunology
PPADS is a P2 receptor antagonist, with IC₅₀s of 68 nM (P2X1) and 214 nM (P2X3). PPADS acts as an ATP (nucleotide) mimetic and competes with ATP for its binding site on P2 receptors. PPADS is also a reversible competitive antagonist of the NAADP receptor. PPADS reverses nociceptive hypersensitivity and reduces the increased NO/NOS system and IL-1β in both peripheral and central steps of nervous system .

HY-157655

Cafedrine-theodrenaline	Adrenergic Receptor	Cardiovascular Disease
Cafedrine-theodrenaline can stimulate the cardiovascular system through β-adrenergic receptor mediation, increasing arterial pressure, stroke volume, and cardiac output, while reducing peripheral vascular resistance, thereby supporting overall cardiac function. Cafedrine-theodrenaline helps maintain blood pressure during hypotensive episodes without causing significant tachycardia .

HY-161712

Nampt-IN-12	NAMPT	Cancer
Nampt-IN-12 (compound 9) is a derivative of N-Pyridinylthiophene carboxamide, exhibiting activity against peripheral nerve sheath tumor cells. Nampt-IN-12 is metabolized via the enzymes NAMPT and NMNAT1, both integral to the NAD salvage pathway, into an adenosine diphosphate (AD) derivative, which is an analog of NAD and capable of inhibiting inosine monophosphate dehydrogenase (IMPDH), leading to the accumulation of inosine monophosphate (IMP) within cells. With its favorable ability to cross the blood-brain barrier, Nampt-IN-12 holds potential for research in cancers affecting both the central and peripheral nervous systems .

HY-164728

Pregabalin diacid	Calcium Channel	Neurological Disease
Pregabalin diacid is an impurity of Pregabalin, a lipophilic GABA (γ-aminobutyric acid) analog with anxiolytic and anticonvulsant activity. Pregabalin may act on the α(2)β subunit of voltage-dependent calcium channels, which are widely distributed in the peripheral and central nervous systems. Pregabalin can effectively induce hypoalgesia and improve behavioral disorders .

HY-12560

PNU-282987 free base	nAChR 5-HT Receptor	Neurological Disease
PNU-282987 (free base) is a potent α7 nicotinic acetylcholine receptor (nAChR) agonist with an EC₅₀ of 154 nM. PNU-282987 (free base) is also a functional antagonist of the 5-HT₃ receptor with an IC₅₀ of 4541 nM. PNU-282987 (free base) can be used for the research of central and peripheral nervous systems .

HY-B0206R

Rizatriptan (benzoate) (Standard) MK 462 (Standard)	5-HT Receptor	Neurological Disease
Rizatriptan (benzoate) (Standard) is the analytical standard of Rizatriptan (benzoate). This product is intended for research and analytical applications. Rizatriptan benzoate is the agonist for 5-HT_1B and 5-HT_1D. Rizatriptan benzoate has a peripheral vasoconstrictive effect, penetrates the intact blood-brain barrier, and inhibits pain neurotransmission in the central nervous system .

HY-P3517

β-Endorphin (6-31), human β-EP (6-31), human	Opioid Receptor	Neurological Disease Endocrinology
β-Endorphin, an endogenous opioid neuropeptide, is an opioid receptor agonist. β-Endorphin binds preferentially to μ-opioid receptors and is produced in certain neurons of the central and peripheral nervous system and is one of three endorphins produced in humans. β-Endorphin can be used to reduce stress and maintain homeostasis in the body and is involved in neurological pain perception regulation .

HY-P3609

CR 665 JNJ 38488502; FE 200665	Opioid Receptor	Neurological Disease
CR 665 (JNJ 38488502) is a peripherally selective κ-opioid agonist. CR 665 can activate the kappa opioid receptor with EC₅₀ value of 10.9 nM. CR 665 can be used for the research of peripheral pain .

HY-164049

TG8-260	Prostaglandin Receptor	Inflammation/Immunology
TG8-260 is a second-generation EP2 antagonist developed to alleviate the pathology of central nervous system and peripheral diseases driven by inflammation. TG8-260 can reduce neuroinflammation and gliosis in the hippocampus of rats after pilocarpine-induced persistent epileptic status. Pharmacokinetic data of TG8-260 showed that its plasma half-life was 2.14 hours and its oral bioavailability was 77.3%. TG8-260 is also a potent inhibitor of CYP450 and shows antagonistic activity in inhibiting EP2 receptor-mediated inflammatory gene expression in BV2-hEP2 microglia, which is suitable for studying anti-inflammatory pathways in animal models of peripheral inflammatory diseases .

HY-P1944

Apelin-13	Apelin Receptor (APJ)	Cardiovascular Disease Metabolic Disease
Apelin-13 is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC₅₀ value of 0.37 nM. Apelin-13 is widely distributed in the central and peripheral nervous systems. Apelin-13 has vasodilatory and antihypertensive effects. Apelin-13 also can be used for researching type 2 diabetes and metabolic syndrome .

HY-B0002B

Ondansetron 5+ Cited Publications GR 38032; SN 307	5-HT Receptor	Neurological Disease Cancer
Ondansetron (GR 38032; SN 307) is a highly selective 5-HT₃ receptor antagonist, with IC₅₀ value of 103 pM. Ondansetron exerts antiemetic effects by antagonizing 5-HT receptor located on local neurons in the peripheral and central nervous system. Ondansetron suppresses nausea and vomiting caused by chemotherapy and radiation therapy. Ondansetron has orally bioactivity .

HY-12560C

(S)-PNU-282987 hydrochloride	nAChR 5-HT Receptor	Neurological Disease
(S)-PNU-282987 hydrochloride is an isoform of PNU-282987 (HY-12560). PNU-282987 (free base) is a potent α7 nicotinic acetylcholine receptor (nAChR) agonist with an EC₅₀ of 154 nM. PNU-282987 (free base) is also a functional antagonist of the 5-HT₃ receptor with an IC₅₀ of 4541 nM. PNU-282987 (free base) can be used for the research of central and peripheral nervous systems .

HY-19057

Vatinoxan MK-467; L-659066	Adrenergic Receptor	Cardiovascular Disease Neurological Disease
Vatinoxan (MK-467) is an alpha 2-adrenergic receptor antagonist. The peripheral selectivity of Vatinoxan determines that it has limited penetration across the blood-brain barrier and therefore has low concentrations in the central nervous system. Vatinoxan antagonizes alpha 2-adrenergic receptor receptors by binding to them, thereby reducing or preventing cardiovascular effects caused by α2-adrenergic agonists. Vatinoxan can be used in studies of cardiovascular effects, sedation and analgesia .

HY-164495

Sob-AM2	FAAH Thyroid Hormone Receptor	Inflammation/Immunology Endocrinology
Sob-AM2 is a potent substrate (K_m=1.3 μM) targeting fatty acid amide hydrolase (FAAH) expressed in the brain and has blood-brain barrier permeability. Sob-AM2 delivers high concentrations of Sobetirome (HY-14823) to the central nervous system with minimal peripheral systemic dose, thereby stimulating central thyroid hormone receptor β (TRβ). In addition, Sob-AM2 can prevent myelin and axon degeneration in experimental autoimmune encephalomyelitis (EAE) mice .

HY-B0002BR

Ondansetron (Standard)	5-HT Receptor	Neurological Disease Cancer
Ondansetron (Standard) is the analytical standard of Ondansetron. This product is intended for research and analytical applications. Ondansetron (GR 38032; SN 307) is a highly selective 5-HT₃ receptor antagonist, with IC₅₀ value of 103 pM. Ondansetron exerts antiemetic effects by antagonizing 5-HT receptor located on local neurons in the peripheral and central nervous system. Ondansetron suppresses nausea and vomiting caused by chemotherapy and radiation therapy. Ondansetron has orally bioactivity .

HY-156730

KT-333	Molecular Glues STAT	Cancer
KT-333 is a molecular glues that degrades STAT3 protein. KT-333 mediates the selective degradation of STAT3 through the ubiquitin-proteasome system by binding to STAT3 protein and E3 ubiquitin ligase von Hippel-Lindau protein (VHL). KT-333 has strong selectivity for STAT3 protein degradation and good antitumor activity. KT-333 can be used in the study of hematologic malignancies such as large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL) .

HY-P3019

Urocortin III (human)	CRFR	Cardiovascular Disease Neurological Disease Endocrinology
Urocortin III (human) is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) selectively binds to type 2 CRF receptors with K_i values of 13.5, 21.7, and >100 nM for mCRF2β, rCRF2α, and hCRF1, respectively. Urocortin III (human) mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion .

HY-156730B

KT-333 diammonium	Molecular Glues STAT	Cancer
KT-333 diammonium is a molecular glues that degrades STAT3 protein. KT-333 diammonium mediates the selective degradation of STAT3 through the ubiquitin-proteasome system by binding to STAT3 protein and E3 ubiquitin ligase von Hippel-Lindau protein (VHL). KT-333 diammonium has strong selectivity for STAT3 protein degradation and good antitumor activity. KT-333 diammonium can be used in the study of hematologic malignancies such as large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL) .

HY-156730A

KT-333 ammonium	Molecular Glues STAT	Cancer
KT-333 ammonium (Compound A) is a molecular glues that degrades STAT3 protein. KT-333 ammonium mediates the selective degradation of STAT3 through the ubiquitin-proteasome system by binding to STAT3 protein and E3 ubiquitin ligase von Hippel-Lindau protein (VHL). KT-333 ammonium has strong selectivity for STAT3 protein degradation and good antitumor activity. KT-333 ammonium can be used in the study of hematologic malignancies such as large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL) .

HY-P0244A

Dermorphin TFA	Opioid Receptor	Neurological Disease
Dermorphin TFA is a natural heptapeptide μ-opioid receptor (MOR) agonist found in amphibian skin. Inhibition of neuropathic pain .

HY-P0244

Dermorphin	Opioid Receptor	Neurological Disease
Dermorphin is a natural heptapeptide μ-opioid receptor (MOR) agonist found in amphibian skin. Inhibition of neuropathic pain .

HY-137055

PF-3774076	Others	Others
PF-3774076 is a highly central nervous system (CNS) penetrant, potent, and selective human α1A-adrenoceptor partial agonist. It exhibits good potency and selectivity in multiple binding and functional assays. PF-3774076 increases peak urethral pressure in anesthetized female dogs in a dose-dependent manner via a central mechanism. PF-3774076 affects both the proximal and distal portions of the urethra in vivo. These properties suggest that PF-3774076 may have significant benefit in the treatment of stress urinary incontinence (SUI) as a CNS-penetrant α1A receptor partial agonist. However, despite its partial agonism and selectivity for α1A receptors, PF-3774076 failed to provide adequate safety differences in in vivo models of cardiovascular function. This may be due to the simultaneous activation of both peripheral and central α1A receptors. These data suggest that while central α1A partial agonists may have significant benefit in the treatment of SUI, this class of agents may have difficulty achieving the desired urethral selectivity without affecting cardiovascular function.

Cat. No.	Product Name

HY-L0116V

Asinex Macrocycles for RNA Library

1,065 compounds

Macrocycles are promising scaffolds for the design of novel RNA targeting molecules. This collection of macrocycles for RNA consists of very diverse, drug-like molecules which incorporate certain known RNA-recognition elements (e.g. nucleobase ring systems and analogs) distributed within macrocyclic rings or peripheral fragments. As macrocyclic molecules tend to be larger than traditional screening molecules, it is vital to carefully assess and control their physicochemical properties. All macrocycles have been tested for aqueous and DMSO solubility with cutoffs applied at 10 mM in DMSO and 50 µM in PBS (pH 7.4); PAMPA permeability has also been tested for representative set of macrocycles.

HY-L121

5-HT Receptor Compound Library

340 compounds

5-HT receptors, also called Serotonin receptors, are a group of G protein-coupled receptors (GPCRs) and ligand-gated ion channels (LGICs) found in the central and peripheral nervous systems. These receptors are now classified into seven families, 5-HT1–7, comprising a total of 14 structurally and pharmacologically distinct mammalian 5-HT receptor subtypes. The 5-HT receptors influence various biological and neurological processes such as aggression, anxiety, appetite, cognition, learning, memory, mood, nausea, sleep, andthermoregulation. The serotonin receptors are the target of a variety of pharmaceutical drugs, including many antidepressants, antipsychotics, anorectics, antiemetics, gastroprokinetic agents, antimigraine agents, hallucinogens, and entactogens.

MCE 5-HT Receptor Compound Library consists of 340 5-HT receptor inhibitors and activators, which can be used for neuropsychiatric disorders drugs discovery.

Cat. No.	Product Name	Target	Research Area